Wegovy for PCOS: what changes before and after treatment, and what doesn't

The biggest myth: Wegovy treats PCOS directly

The most common misconception is that semaglutide works on PCOS the way a hormonal treatment does, by targeting the ovaries, the pituitary gland, or the androgen pathways directly. It doesn't. Wegovy is a GLP-1 receptor agonist, and its licensed purpose is weight management alongside a reduced-calorie diet and increased activity, as described by the NHS medicines page for semaglutide. The hormonal shifts that some women experience are largely downstream of weight loss and improved insulin sensitivity, two things that genuinely do matter in PCOS, where insulin resistance is a central driver of raised androgens, irregular cycles and other symptoms.

That distinction matters practically. A woman who loses 10–15% of her body weight through any effective method tends to see improvements in LH/FSH ratios, androgen levels and cycle regularity. Semaglutide can produce that level of weight reduction in many people, and STEP 1, the landmark 68-week trial published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% at the 2.4mg maintenance dose, and you can read about Wegovy results before and after to see how those outcomes have translated across real patients. The hormone changes follow from there, they are real, but they are not a separate, reliable treatment effect that would appear without meaningful weight loss.

Framing this clearly matters because it sets honest expectations. If your weight does not respond significantly to semaglutide, the secondary hormonal benefits are unlikely to materialise either.

What actually changes, and the timeline involved

Women with PCOS who respond well to Wegovy and achieve sustained weight loss most commonly report three types of change. First, reductions in fasting insulin and improvements in insulin resistance markers, which tend to emerge within the first three to six months as weight falls. Second, some reduction in circulating androgens (free testosterone in particular) which can translate to reduced hirsutism and acne over a longer period, typically six months or more. Third, and the one most people are searching for: improved menstrual regularity. Evidence here is encouraging but comes from smaller trials rather than large randomised studies, so it cannot be predicted individually.

The timeline is genuinely unhurried. Titration for Wegovy begins at 0.25mg and steps up every four weeks through 0.5mg, 1mg, 1.7mg to the 2.4mg maintenance dose, sometimes higher with the newer 7.2mg option. Full therapeutic effect builds over months, not weeks. A realistic window to assess meaningful hormonal response would be six to twelve months at a stable maintenance dose. That is a long commitment, and how long Wegovy takes to work is worth understanding in full before starting.

One practical note: many women plan their first consultation around a quiet patch, not a holiday, not the week before a work deadline. Getting started on a Monday before the 12pm cut-off means same-day clinical review and next-working-day dispatch if approved, so timing your start when you can settle into a routine genuinely helps.

What remains uncertain, and who to involve in the decision

The honest gaps are worth naming. There are no large, long-term randomised controlled trials comparing semaglutide with standard PCOS treatments (metformin, combined oral contraceptives, or anti-androgen therapy) in a head-to-head design. The studies that exist are mostly shorter, smaller and use varying endpoints. Fertility outcomes specifically are not well characterised: there are case reports of ovulation returning in women with PCOS after significant weight loss on GLP-1 medicines, which is welcome news for some women and an unintended complication for others not intending pregnancy.

That last point is not trivial. Semaglutide is not recommended during pregnancy, and a wash-out period is needed before trying to conceive, your prescriber will discuss the specific timeframe based on current guidance. If there is any chance of pregnancy during treatment, effective contraception is essential. Your prescriber will also want to know about any existing treatment with metformin, spironolactone or hormonal therapies, since these interact with the overall clinical picture.

A GP or gynaecologist familiar with your PCOS history adds important context that a weight-management consultation alone may not capture. The nume clinical team works within weight-management licensing, and we will always flag where specialist input should run alongside treatment. You can also review how Wegovy works in detail, or explore the evidence on Wegovy weight loss before and after treatment for a broader picture of who tends to respond and how.

Wegovy eligibility if you have PCOS, the private route explained

Wegovy is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. PCOS itself can qualify as that condition in a private clinical assessment, alongside other common PCOS-related comorbidities such as insulin resistance, type 2 diabetes or hypertension. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone never determines suitability, the prescriber considers your full medical picture, current medications and any contraindications before making a decision.

On the NHS, access to semaglutide through NICE guidance TA875 is routed through specialist weight-management services with specific criteria and typically long waiting lists. The private route through a regulated pharmacy like nume removes the waiting list and the referral requirement, subject to clinical approval. If you want to explore whether you qualify, starting a free consultation is the first step, there is no commitment, and our prescribers review every application personally. You can also read about how to access Wegovy safely in the UK and what to look for in a registered provider. For more on Wegovy before and after experiences, including how results differ across different starting points, that page covers the evidence in full.